Literature DB >> 23729617

Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease.

Nandakumar S Narayanan1, Robert L Rodnitzky, Ergun Y Uc.   

Abstract

Cognitive dysfunction is a common symptom of Parkinson's disease (PD) that causes significant morbidity and mortality. The severity of these symptoms ranges from minor executive symptoms to frank dementia involving multiple domains. In the present review, we will concentrate on the aspects of cognitive impairment associated with prefrontal dopaminergic dysfunction, seen in non-demented patients with PD. These symptoms include executive dysfunction and disorders of thought, such as hallucinations and psychosis. Such symptoms may go on to predict dementia related to PD, which involves amnestic dysfunction and is typically seen later in the disease. Cognitive symptoms are associated with dysfunction in cholinergic circuits, in addition to the abnormalities in the prefrontal dopaminergic system. These circuits can be carefully studied and evaluated in PD, and could be leveraged to treat difficult clinical problems related to cognitive symptoms of PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23729617      PMCID: PMC3836593          DOI: 10.1515/revneuro-2013-0004

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  150 in total

1.  Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom.

Authors:  Peter Hobson; Jolyon Meara
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

2.  Psychiatric changes in patients treated with levodopa. I. The clinical experiment.

Authors:  W Knopp
Journal:  Neurology       Date:  1970-12       Impact factor: 9.910

3.  Is choline acetyltransferase present in synaptic vesicles?

Authors:  F Fonnum
Journal:  Biochem Pharmacol       Date:  1966-10       Impact factor: 5.858

4.  Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD).

Authors:  C E Morrison; J C Borod; M F Brin; T D Hälbig; C W Olanow
Journal:  J Neural Transm (Vienna)       Date:  2004-05-12       Impact factor: 3.575

5.  Microtopography of tyrosine hydroxylase, glutamic acid decarboxylase, and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and Parkinsonian brains.

Authors:  F Javoy-Agid; A Ploska; Y Agid
Journal:  J Neurochem       Date:  1981-11       Impact factor: 5.372

6.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's Disease.

Authors:  T Arendt; V Bigl; A Arendt; A Tennstedt
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

7.  Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

Authors:  B Scatton; F Javoy-Agid; L Rouquier; B Dubois; Y Agid
Journal:  Brain Res       Date:  1983-09-26       Impact factor: 3.252

8.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

Authors:  E K Perry; M Curtis; D J Dick; J M Candy; J R Atack; C A Bloxham; G Blessed; A Fairbairn; B E Tomlinson; R H Perry
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-05       Impact factor: 10.154

9.  Is the mesocortical dopaminergic system involved in Parkinson disease?

Authors:  F Javoy-Agid; Y Agid
Journal:  Neurology       Date:  1980-12       Impact factor: 9.910

10.  Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism.

Authors:  Thomas Foltynie; Terry E Goldberg; Simon G J Lewis; Andrew D Blackwell; Bhaskar S Kolachana; Daniel R Weinberger; Trevor W Robbins; Roger A Barker
Journal:  Mov Disord       Date:  2004-08       Impact factor: 10.338

View more
  70 in total

Review 1.  Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.

Authors:  Saranya Sundaram; Rachel L Hughes; Eric Peterson; Eva M Müller-Oehring; Helen M Brontë-Stewart; Kathleen L Poston; Afik Faerman; Chloe Bhowmick; Tilman Schulte
Journal:  Neurosci Biobehav Rev       Date:  2019-05-24       Impact factor: 8.989

2.  Release parameters during progressive degeneration of dopamine neurons in a mouse model reveal earlier impairment of spontaneous than forced behaviors.

Authors:  Yuan-Hao Chen; Tsung-Hsun Hsieh; Tung-Tai Kuo; Jen-Hsin Kao; Kuo-Hsing Ma; Eagle Yi-Kung Huang; Yu-Ching Chou; Lars Olson; Barry J Hoffer
Journal:  J Neurochem       Date:  2019-05-09       Impact factor: 5.372

3.  Prefrontal D1 dopamine signaling is necessary for temporal expectation during reaction time performance.

Authors:  K L Parker; S L Alberico; A D Miller; N S Narayanan
Journal:  Neuroscience       Date:  2013-10-10       Impact factor: 3.590

4.  Prefrontal D1 Dopamine-Receptor Neurons and Delta Resonance in Interval Timing.

Authors:  Young-Cho Kim; Nandakumar S Narayanan
Journal:  Cereb Cortex       Date:  2019-05-01       Impact factor: 5.357

5.  Mid-frontal theta activity is diminished during cognitive control in Parkinson's disease.

Authors:  Arun Singh; Sarah Pirio Richardson; Nandakumar Narayanan; James F Cavanagh
Journal:  Neuropsychologia       Date:  2018-05-23       Impact factor: 3.139

6.  The relation of anxiety and cognition in Parkinson's disease.

Authors:  Gretchen O Reynolds; Kristine K Hanna; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychology       Date:  2017-04-20       Impact factor: 3.295

Review 7.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 8.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

9.  VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.

Authors:  Chen Wang; Mengxi Niu; Zehua Zhou; Xiaoyuan Zheng; Lingzhi Zhang; Ye Tian; Xiaojun Yu; Guojun Bu; Huaxi Xu; Qilin Ma; Yun-Wu Zhang
Journal:  Neurobiol Aging       Date:  2016-05-21       Impact factor: 4.673

10.  The Vulnerable Ventral Tegmental Area in Parkinson's Disease.

Authors:  Stephanie L Alberico; Martin D Cassell; Nandakumar S Narayanan
Journal:  Basal Ganglia       Date:  2015-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.